Dr. Marc Sabatine, MD

• Cardiology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Mass General Hospital

  Residency Hospital, 2003

• Massachusetts General Hospital

  Fellowship Hospital, 2002

• Massachusetts General Hospital

  Residency Hospital, 1998

• Massachusetts General Hospital

  Internship Hospital, 1996

• Harvard Medical School

  Medical School, 1995

• Increases in Myocardial Workload Induced by Rapid Atrial Pacing Trigger Alterations in Global Metabolism, 2014-06-16

• Detection of High-Risk Atherosclerotic Plaque Report of the NHLBI Working Group on Current Status and Future Directions, 2013-03-14

• Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl, 2021-08-27

• Genetic Variants inABCB1,CYP2C19, and Cardiovascular Outcomes Following Treatment with Clopidogrel and Prasugrel, 2010-10-16

• A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia, 2023-04-10

• A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease, 2011-06-19

• The Effect of PCSK9 Inhibition on the Risk of Venous Thromboembolism, 2020-03-29

• Heart Failure Endpoints in Cardiovascular Outcome Trials of SGLT2 inhibitors in Patients with Type 2 Diabetes: A Critical Evaluation of Clinical and Regulatory Issues, 2019-12-16

• Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease, 2021-01-12

• Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry, 2009-04-16

• Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction A Prespecified Analysis of DAPA-HF, 2020-09-04

• Early Dynamic Risk Stratification with Baseline Troponin Levels and 90-minute ST Segment Resolution to Predict 30 Day Cardiovascular Mortality in STEMI: Analysis from CLARITY TIMI-28, 2010-04-23

• Publisher Correction: Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes, 2022-09-30

• Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials, 2019-09-18

• Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF, 2020-07-16

• Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF, 2022-08-16

• Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries, 2022-11-14

• Guided Antithrombotic Therapy - Current Status and Future Research Direction: Report on a National Heart, Lung and Blood Institute Working Group, 2012-09-25

• Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER, 2022-08-27

• The American Heart Association's Vascular Diseases Strategically Focused Research Network, 2020-01-23

• Reduced-FunctionCYP2C19Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis, 2010-10-27

• Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease, 2016-07-26

• Coding variants inRPL3LandMYZAPincrease risk of atrial fibrillation, 2018-06-12

• Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China Hospital-Level Differences in Care and Outcomes Among Patients With Acute STEMI in China, 2020-10-23

• Combining High-Sensitivity Troponin with the AHA/ACC Cholesterol Guidelines To Guide Evolocumab Therapy, 2021-07-19

• Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease, 2011-12-16

• The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism, 2020-10-26

• Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial, 2011-11-17

• Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis, 2023-05-22

• Myocardial infarction accelerates atherosclerosis, 2012-07-19

• No association betweenAPOEgenotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab, 2022-04-11

• Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial, 2022-07-19

• Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain, 2014-06-05

• Impact ofADCY9Genotype on Response to Anacetrapib, 2019-07-23

• Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors, 2022-06-17

• Metabolic Signatures of Exercise in Human Plasma, 2010-05-26

• Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial, 2019-11-17

• Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease, 2020-11-13

• Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel, 2009-04-14

• Myocardial Ischemia Induced by Rapid Atrial Pacing Causes Troponin T Release Detectable by a High-Sensitivity Assay: Insights from a Coronary Sinus Sampling Study, 2011-06-14

• Validation of an Automated Safety Surveillance System with Prospective, Randomized Trial Data, 2008-11-17

• Sex, Permanent Drug Discontinuation and Study Retention in Clinical Trials: Insights from the TIMI trials, 2021-02-15

• Prognostic Utility of Secretory Phospholipase A2in Patients with Stable Coronary Artery Disease, 2011-07-22

• Lipoprotein (a) For Risk Assessment in Patients with Established Coronary Artery Disease, 2013-10-23

• Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54, 2019-06-20

• Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes, 2022-08-30

• Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF P. Dewanet al., 2021-01-18

• Stroke genetics informs drug discovery and risk prediction across ancestries, 2022-09-30

• Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease, 2014-04-09

• A missense variant inPLECincreases risk of atrial fibrillation, 2017-10-24

• Secretory Phospholipase A2-IIA and Cardiovascular Disease A Mendelian Randomization Study, 2013-11-19

• Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?, 2020-11-09

• Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial, 2023-01-24

• Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF J.H. Buttet al., 2021-11-24

• Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants, 2022-12-06

• Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus, 2019-08-31

• Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER, 2022-11-07

• Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF C. Adamsonet al., 2022-08-22